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THE LANCET 
But is it food? 
Martijn B Katan, Pieter van't Veer 
The past year saw an acceleration of the trend towards 
products halfway between foods and pharmaceuticals. 
Sucrose polyester looks and tastes like fat, but it is not 
absorbed because it contains bonds between sucrose and 
fatty acids that cannot be hydrolysed by pancreatic lipases. 
Critics questioned whether the reduction in fat intake 
would make people lose weight, and worried about losses 
of fat-soluble vitamins (N Engl J Med 1996; 335" 669). 
Another hitech food came from Finland. Miettinen et al 
found that converting the plant sterol sitosterol into 
sitostanol ester made it an effective cholesterol-lowering 
agent; a 10% suspension in margarine lowered LDL 
cholesterol by 13%. The margarine is a commercial 
success, but is it a food? 
Vitamin supplements are another example of 
"nutraceuticals". The CHAOS trial (Stephens) provided 
the first experimental evidence that vitamin E can reduce 
coronary disease (though mortality outcomes were still 
worrying). Carotene supplements fared less well. Carotene 
intake and plasma carotene levels are inversely associated 
with risk of cancer in epidemiological studies, but  
randomised trials of the effect of high-dose carotene 
supplements on risk of lung cancer in smokers yielded 
disappointing results: the CARET trial (Omenn) had to 
be stopped early because of a raised incidence of cancer, 
confirming earlier findings (Lancet 1996; 347: 249). In a 
low-risk population, total cancer incidence was unaffected 
by carotene supplements (N EnglJ Med 1996; 334: 145). 
The hypothesis that eating less fat will reduce the risk of 
breast cancer received a blow from a pooled analysis of 
seven prospective studies including almost 5000 cases; no 
association with dietary fat was seen over a wide range of 
intake (Hunter). 
However, the association between high intakes of fruits 
and vegetables and reduced risk of cancer remains firm. 
Hollman et al defeated conventional wisdom by showing 
that human beings absorb flavonoid glycosides (Free Rad 
Biol Med, 1996; 21:  73), but evidence that flavonoids 
protect against heart disease is still inconsistent (Ann 
Intern Med 1996; 125: 364, BMJ 1996; 312: 458). We 
should not ignore the potential of bioactive compounds to 
do harm, as testified by the adverse effects of coffee 
diterpenes on blood lipids and transaminases (Urgert). 
Both beneficial and adverse effects are modulated by 
nutrient gene interactions, and this will inevitably produce 
demands to tailor nutr i t ional  advice to genetic 
susceptibility. But should we know whether we have the 
proper allele of N-acetyltransferase before enjoying our 
barbecued steak (Lancet 1996; 347: 1372)? Genetic 
screening cannot substitute for prudent dietary habits. 
One of the greatest recent advances is the finding that 
periconceptional intake of folic acid can prevent neural- 
Lancet 1996;  348  (suppl II): 15 
Wageningen Agricultural University, Department of Human Nutrition 
and Epidemiology, Bomenweg 2, 6703 HD Wageningen, 
Netherlands (M B Katan PhD, P van't Veer PhD) 
tube defects. Increased consumption of folic acid might 
also reduce the risk for thrombosis, heart disease, and 
cancer. But again foods are at risk of losing out to 
pharmaceuticals because both the concentration and the 
bioavailability of folic acid in foods may be too low (Lancet 
1996; 347: 657). 
Plant breeders might be able to produce foods higher in 
available folic acid, but will consumers pay a premium for 
Super-Folic Broccoli? 
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